White House AnnouncementOn October 21, 2015, the Collaborative for REMS Education (CO*RE) joined the Obama Administration, and a number of public and private sector partners, to announce new efforts to address the prescription drug abuse and heroin epidemic.

The announcement is part of a community discussion in Charleston, West Virginia. The President will meet with individuals and families who have been directly affected by the epidemic, professionals in law enforcement, federal agencies, and healthcare clinicians and organizations.  The event highlights the important work already underway as well as announcing new efforts to address the epidemic.

The announcement was part of a community discussion in Charleston, West Virginia. The President met with individuals and families who have been directly affected by the epidemic, professionals in law enforcement, federal agencies, and healthcare clinicians and organizations.  The event highlighted the important work already underway as well as the announcement of new efforts to address the epidemic.

The recorded event is available Here.

Since 2013 CO*RE and its partner organizations have educated more than 110,000 prescribing clinicians across the country and plan to educate an additional 25,000 to 35,000 clinicians in 2016. Harnassing its  extensive collective communication channels, CO*RE has brought awareness of opioid misuse abuse to over a million healthcare professionals across the country.

The mission of CO*RE is to promote individual and population health and public safety through timely, evidence-based, outcome-oriented and interprofessional education related to the comprehensive management of pain, addiction, and their co-morbidities.

CORE Team Award

The CO*RE team receiving the collaboration award from the Alliance for Continuing Education in the Health Professions (ACEhp) at the 2015 annual conference in Grapevine, Texas.
Primary care providers, pain management, addiction and palliative care specialists, and clinicians representing all arenas of the health care system struggle to successfully manage their patients' pain. For many patients, long-acting and extended-release opioid medications constitute an effective and valuable element in the pain management plan. However, opioid prescription involves many complex issues of misuse, abuse, addiction, adverse effects, and fear of legal and regulatory action. In order to address risk and safety concerns, reduce serious adverse outcomes, and simultaneously ensure that pain patients maintain necessary access to opioids, the U. S. Food and Drug Administration (FDA) has developed a Risk Evaluation and Mitigation Strategy (REMS) that applies to all long-acting and extended-release opioid medications.

This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies.  Please see http://ce.er-la-opioidrems.com/IwgCEUI/rems/pdf/List_of_RPC_Companies.pdf for a listing of the member companies.  This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.

Menu Search